When to Order Imaging for Staging and Follow-Up of Leukemia: ACR Appropriateness Decoded

When to Order Imaging for Staging and Follow-Up of Leukemia: ACR Appropriateness Decoded

A new leukemia diagnosis triggers a cascade of clinical decisions, and determining the extent of disease is paramount. While bone marrow biopsy and lab work are central, imaging’s role can be ambiguous, especially in asymptomatic patients. You’re managing a newly diagnosed patient, perhaps a child with Acute Lymphoblastic Leukemia (ALL) or an adult with a chronic form like Chronic Lymphocytic Leukemia (CLL). Do they need a chest X-ray? A full-body PET/CT? The American College of Radiology (ACR) provides evidence-based guidelines to navigate these questions, helping you choose the right study, avoid unnecessary radiation, and ensure accurate staging and follow-up. This article distills the latest ACR recommendations for leukemia imaging into a scannable, practical guide.

What Does ACR Staging and Follow-Up of Leukemia Cover?

This ACR Appropriateness Criteria topic focuses on selecting the correct imaging modalities for the initial staging and subsequent monitoring of various leukemias. The guidelines address common clinical scenarios across different patient populations (pediatric and adult) and leukemia subtypes, including Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), and Hairy Cell Leukemia. Scenarios range from initial, asymptomatic presentations to post-therapy evaluation and surveillance for disease transformation. The primary goal is to identify extramedullary disease—leukemic involvement outside the bone marrow—which can significantly impact prognosis and treatment strategy. This topic does not cover imaging for suspected leukemia prior to diagnosis or for evaluating complications of therapy, such as infection or venous thromboembolism, which are addressed in separate ACR guidelines.

What Imaging Should I Order for Staging and Follow-Up of Leukemia? Recommendations by Clinical Scenario

Imaging for leukemia is highly context-dependent, with recommendations varying significantly by leukemia type, patient age, and clinical question. For many asymptomatic initial staging scenarios, particularly in chronic leukemias, imaging is often not indicated.

For a child with newly diagnosed, asymptomatic Acute Lymphoblastic Leukemia (ALL), routine systemic imaging is generally not recommended. However, the ACR notes that a Radiography chest is rated May be appropriate (Disagreement) to assess for a mediastinal mass. In male children, due to the risk of testicular involvement, a US scrotum is also rated May be appropriate (Disagreement). For an asymptomatic adult with new ALL, a CT chest without IV contrast is considered May be appropriate (Disagreement), again primarily to evaluate the mediastinum. In contrast, for an adult undergoing post-therapy evaluation for ALL with known extramedullary disease at diagnosis, more comprehensive imaging like CT chest abdomen pelvis with IV contrast or FDG-PET/CT is Usually appropriate to assess treatment response.

In adults with asymptomatic, initial staging for Acute Myeloid Leukemia (AML) or promyelocytic leukemia, FDG-PET/CT is rated Usually appropriate to detect extramedullary disease, such as myeloid sarcomas. Simpler studies like a chest radiograph or a non-contrast head CT are sometimes considered and are rated May be appropriate (Disagreement).

For chronic leukemias, the imaging approach is more conservative. For an asymptomatic adult at initial staging for Chronic Myeloid Leukemia (CML), nearly all imaging studies are rated Usually not appropriate. Similarly, for asymptomatic initial staging of Chronic Lymphocytic Leukemia (CLL), most imaging is not indicated, though CT chest abdomen pelvis with IV contrast and FDG-PET/CT are rated May be appropriate (Disagreement), reflecting their use in select cases with high-risk features. However, the role of imaging changes dramatically if histologic transformation (i.e., Richter syndrome) is suspected in a patient with CLL. In this high-stakes scenario, both CT chest abdomen pelvis with IV contrast and FDG-PET/CT are Usually appropriate to identify aggressive lymphoma.

Finally, for asymptomatic initial staging of hairy cell leukemia, where splenomegaly is a key feature, CT chest abdomen pelvis with or without IV contrast is rated May be appropriate to assess the extent of organ involvement and adenopathy.

ACR Imaging Recommendations Table

Adult vs. Pediatric Staging and Follow-Up of Leukemia Imaging: Radiation Dose Tradeoffs

The principle of As Low As Reasonably Achievable (ALARA) is a cornerstone of pediatric imaging, and the ACR guidelines for leukemia reflect this. Children are more radiosensitive than adults, and their longer life expectancy provides more time for potential long-term effects of radiation exposure to manifest. Consequently, imaging recommendations for children with leukemia are often more restrictive, and when imaging is necessary, lower-dose modalities are preferred.

For the initial staging of asymptomatic ALL, the pediatric variants highlight this difference. While a chest radiograph is sometimes considered, extensive cross-sectional imaging like CT is rated Usually not appropriate. The pediatric relative radiation level (RRL) for a chest radiograph is minimal (☢ <0.03 mSv), whereas a pediatric chest CT carries a significantly higher dose (☢ ☢ ☢ ☢ 3-10 mSv). This contrasts with the adult ALL staging scenario, where a non-contrast chest CT is rated May be appropriate (Disagreement). The specific recommendation for a scrotal ultrasound in male children with ALL is another key pediatric consideration, as it uses no ionizing radiation to evaluate a common site of extramedullary disease.

Imaging Protocol Details for Staging and Follow-Up of Leukemia

Once you’ve decided on the right study based on the clinical scenario, ensuring it’s performed correctly is the next critical step. The technical parameters of an imaging protocol—such as the use and timing of intravenous contrast, slice thickness in CT, or specific sequences in MRI—can significantly impact diagnostic quality. Our protocol guides provide detailed, practical information for the key studies recommended in these guidelines.

• US Scrotum
• CT Chest Without Contrast
• CT Chest/Abdomen/Pelvis with IV Contrast

Tools to Help You Order the Right Study

Navigating imaging guidelines can be complex, especially when managing uncommon presentations or multiple comorbidities. GigHz offers a suite of tools designed to support evidence-based clinical decision-making at the point of care.

For clinical questions beyond leukemia, the ACR Appropriateness Criteria Lookup provides a fast, searchable interface to the complete ACR guidelines, covering thousands of clinical variants across all organ systems. It helps you find the most appropriate study for your patient’s specific situation.

To ensure optimal image acquisition, the Imaging Protocol Library offers detailed, step-by-step protocols for a wide range of CT, MRI, and ultrasound examinations. This resource is invaluable for standardizing techniques and ensuring diagnostic quality.

When discussing the risks and benefits of imaging with patients, especially concerning radiation, the Radiation Dose Calculator is an essential tool. It helps estimate cumulative radiation exposure from various imaging studies, facilitating informed consent and patient education.

Why is imaging not always needed for initial leukemia staging?

Leukemia is primarily a disease of the bone marrow and peripheral blood. The diagnosis and initial risk stratification rely heavily on bone marrow aspirate/biopsy, flow cytometry, cytogenetics, and molecular studies. For many asymptomatic patients, particularly with chronic leukemias like CML, imaging does not add significant information to these results and would expose the patient to unnecessary radiation and cost. Imaging is reserved for situations where there is a clinical suspicion of extramedullary disease (e.g., a palpable mass, focal neurologic deficits) or for specific high-risk subtypes where occult extramedullary involvement is more common and clinically significant (e.g., AML).

What is the primary role of FDG-PET/CT in leukemia?

FDG-PET/CT is highly sensitive for detecting metabolically active disease. Its primary role in leukemia is to identify sites of extramedullary disease, which can appear as focal FDG-avid lesions. This is particularly important in AML for detecting myeloid sarcomas and in CLL when there is suspicion of transformation to an aggressive lymphoma (Richter syndrome), which is typically intensely FDG-avid. It can also be used to assess treatment response in known extramedullary sites. However, it is not useful for evaluating bone marrow involvement, as the marrow is often diffusely hypermetabolic from the leukemia itself, obscuring focal lesions.

When should I specifically order a scrotal ultrasound for a child with ALL?

The testes are a known sanctuary site for acute lymphoblastic leukemia, meaning leukemic cells can persist there despite systemic chemotherapy. While routine screening ultrasound for all asymptomatic male children at diagnosis is controversial (reflected in the ACR’s May be appropriate (Disagreement) rating), it should be strongly considered in any male child with testicular swelling, pain, or a palpable mass. An ultrasound is a non-invasive, radiation-free way to confirm testicular involvement, which would necessitate specific treatment changes, such as local radiation therapy.

What is Richter syndrome, and why does it require aggressive imaging?

Richter syndrome (or Richter’s transformation) is the transformation of chronic lymphocytic leukemia (CLL) into a much more aggressive lymphoma, most commonly diffuse large B-cell lymphoma. This occurs in a subset of CLL patients and carries a very poor prognosis. Clinically, it should be suspected in a patient with CLL who develops rapidly enlarging lymph nodes, fevers, weight loss, and a sharp rise in their LDH level. Because this transformation can occur in any lymph node basin, aggressive imaging with either contrast-enhanced CT of the chest, abdomen, and pelvis or, preferably, an FDG-PET/CT is considered Usually appropriate to identify the most active site of disease for biopsy and to fully stage the high-grade lymphoma.

For asymptomatic CML, why is imaging rated ‘Usually Not Appropriate’?

Chronic Myeloid Leukemia (CML) is characterized by the Philadelphia chromosome (BCR-ABL1 fusion gene). The disease is typically confined to the bone marrow and peripheral blood. Staging and monitoring are based on blood counts and molecular testing (quantitative PCR for BCR-ABL1 transcripts). Extramedullary disease is very rare in the chronic phase of CML. Therefore, performing systemic imaging in an asymptomatic patient at diagnosis provides no additional staging or prognostic information beyond what is obtained from lab tests and would not alter the standard management with tyrosine kinase inhibitors.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026